We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Modulation of mRNA Activity Regulates Thrombin Synthesis

By LabMedica International staff writers
Posted on 23 Feb 2011
A paper described the molecular mechanism that regulates synthesis of thrombin, a protein required for blood clotting but also implicated in processes related to inflammation and tumor metastasis.

Thrombin is a key protease involved in blood coagulation, complement activation, inflammation, angiogenesis, and tumor invasion. More...
While prothrombin production increases when an organism experiences stress, the molecular pathways controlling this process have not been defined. Now, in a paper published in the February 4, 2011, issue of the journal Molecular Cell, investigators at the European Molecular Biology Laboratory (Heidelberg, Germany) have found that prothrombin expression is regulated by a posttranscriptional regulatory mechanism responding to stress and inflammation.

This mechanism is triggered by external stimuli that activate p38 MAPK (p38 mitogen-activated protein kinase), one of the class of mitogen-activated protein kinases that are responsive to stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock, and are involved in cell differentiation and apoptosis.

The activated p38 MAPK stimulates enzymes responsible for manipulating the 3′ end of certain classes of mRNA and phosphorylates the RNA-binding proteins FBP2 and FBP3, which inhibit 3′ end processing of mRNAs. By blocking this inhibitor, p38 MAPK removes an obstacle to thrombin synthesis, and the level of thrombin in the blood increases.

While elevated thrombin production is beneficial to an organism under stress, analysis of liver samples taken from septicemic mice and from cancer patients, revealed that thrombin production increased in response both to widespread inflammation during septicemia and to localized inflammation at the tumor's invasion front.

"Knowing the exact molecules involved, and how they act, has implications for treatment, especially as drugs that inhibit p38 MAPK are already being tested in clinical studies for other conditions,” said contributing author Dr. Matthias Hentze, associate director of the European Molecular Biology Laboratory. Those drugs could be good candidates for potential cancer or septicemia therapies.”

Related Links:

European Molecular Biology Laboratory




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.